BASi (Bioanalytical Systems, Inc.) is reorganizing its Baltimore Clinical Research Unit (CRU) and its UK operations in order to reduce expenses and to improve operating results for these business units and the corporation. The reorganization will result in a reduction of 25 people over both business units. The company expects to lower expenses by $1 million for the first full year of operation following the re-organization.

The Bioanalytical Laboratory associated with the CRU in Baltimore will close and the bioanalytical work associated with clinical research activity will now be conducted in BASi laboratories in West Lafayette, IN, McMinnville, OR, and Warwick, UK. These laboratories have similar or greater capacity to support Baltimore’s sample analysis needs, higher critical mass in instrumentation, and more method development expertise to serve clients, according to the company.

BASi business in the UK has been re-focused on the Bioanalytical Laboratory that serves UK and European customers as well as selected clients from the U.S. This change provides additional opportunities to U.S. clients who are seeking UK or European registration for their products and gives BASi additional capacity for increasing demand for services. The Biomarkers Laboratory will be moved from the UK to West Lafayette. BASi analytical instruments business in the UK continues with a smaller staff focused on sales and service of traditional instrument businesses, along with the Culex Automated Pharmacology System, in both the UK and Europe.

Dr. Edward Chait, BASi executive vice president and chief scientific officer said, “Executing this reorganization is part of the plan to make our acquisitions in Baltimore and the UK more efficient and to improve significantly services to clients. These changes dovetail perfectly with our reorganized business development team. In short, our mandate for 2006 is to stay focused on the big opportunities.”